System4 Technologies GmbH: Universal Therapy Device For COVID-19, COVID-19 Mutations, and Other Virus Variants Unveiled
Possible use in intensive care medicine and treatment of long COVID.
Planned large-scale study on universal use against coronaviruses and other RNA viruses.
BAD ZWISCHENAHN, GERMANY / ACCESSWIRE / April 21, 2021 / The life science company System4 Technologies GmbH has developed a new therapy device for the treatment of Covid patients.
The device, named PI-RNA, is designed to enable universal and fast deactivation of coronaviruses and influenza viruses, their mutations and new variants by means of
a special cold atmospheric plasma procedure. The so-called CAP (Cold Atmospheric Plasma) - technology transfers electrostatically atmospheric anions, in high numbers and densities, into and around the body of the patient. This is achieved through a
Initial off-label-use applications with a special plasma design are promising. Possible use in intensive care medicine and treatment of long COVID. Planned large-scale study on universal use against coronaviruses and other RNA viruses. The life science company System4 Technologies GmbH has developed a new therapy device for the treatment of Covid patients. The device, named PI-RNA, is designed to enable universal and fast deactivation of coronaviruses and influenza viruses, their mutations and new variants by means of a special cold atmospheric plasma procedure. The so-called CAP (Cold Atmospheric Plasma) - technology transfers electrostatically atmospheric anions, in high numbers and densities, into and around
DGAP-Media / 21.04.2021 / 09:30 Initial off-label-use applications with a special plasma design are promising. Possible use in intensive care medicine and treatment of long COVID. Planned large-scale study on universal use against coronaviruses and other RNA viruses. The life science company System4 Technologies GmbH has developed a new therapy device for the treatment of Covid patients.
The device, named PI-RNA, is designed to enable universal and fast deactivation of coronaviruses and influenza viruses, their mutations and new variants by means of
a special cold atmospheric plasma procedure. The so-called CAP (Cold Atmospheric Plasma) - technology transfers electrostatically atmospheric anions, in high numbers and densities, into and around the body of the patient. This is achieved through a